Eden Research Plc
("Eden" or "Company")
Successful trials in Greece to combat Botrytis in grapes
Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that its Greece based licence partner, Redestos S.A ('Redestos'), has carried out successful pre-launch trials on grapes using Eden's plant protection product, 3AEY, which uses low-risk active ingredients and Eden's natural encapsulation technology, GO-E Inside™, to combat botrytis, a fungus that affects many plants and is a major concern for grape producers and vineyards.
The trials have been carried out in advance of completion of the EU regulatory process which is expected in spring 2015, and mark the early stages of preparation for commercial launch in Greece and sales of products containing Eden's active ingredients and technology. The work reinforces the results seen in Eden's regulatory trials across the southern Mediterranean zone where 3AEY showed comparable disease control to conventional synthetic products.
Eden entered into a Licence Agreement with Redestos in 2006 to develop and commercialise agricultural products to treat botrytis in grapes which will be sold in Greece and the Balkan states. The results of the trials have shown that the product is effective against botrytis, including when infestation has already occurred, and that it did not cause any phytotoxicity issue, i.e. the discolouring of the grapes.
Sean Smith, Chief Executive Officer of Eden, said: "We are delighted that our technology has stood up to the rigorous testing that our partners in Greece have subjected it to and that testing is taking place now, ahead of the completion of EU regulatory approval for our product, 3AEY, as this will allow Redestos to move to commercial launch shortly after we receive final approval."
Eden Research plc |
www.edenresearch.com |
Sean Smith, Chief Executive Officer |
Tel: 01993 862 761 |
Alex Abrey, Chief Financial Officer |
|
|
|
W H Ireland Limited |
Tel: 0117 945 3471 |
John Wakefield / Ed Allsopp |
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |
Notes:
Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic hydrophobic compounds. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into licence agreements.
In May of 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit www.edenresearch.com
